Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting
January 29 2018 - 8:00AM
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that data from preclinical studies evaluating its lead
antifungal candidate rezafungin acetate, formerly known as CD101
IV, will be presented at two upcoming medical conferences.
Rezafungin abstracts have been accepted for presentation at both
the 8th Advances Against Aspergillosis (AAA) Conference in Lisbon,
Portugal from February 1-3 and at the 2018 BMT Tandem Meetings in
Salt Lake City, Utah from February 21-25. The BMT Tandem Meetings
are the combined annual meetings of the Center for International
Blood & Marrow Transplant Research (CIBMTR) and the American
Society for Blood and Marrow Transplantation (ASBMT).
“Cidara’s presentations at these two important conferences
highlight our commitment to exploring the full clinical utility of
rezafungin with our scientific collaborators,” said Jeffrey Stein,
Ph.D., president and chief executive officer of Cidara. “This
includes the potential of rezafungin in patients with hematologic
diseases and those undergoing transplantation who are at
significant risk of invasive fungal infections, often with high
mortality.”
A total of four poster presentations will highlight the efficacy
of rezafungin against serious invasive fungal infections (IFIs),
including Candida, Aspergillus and Pneumocystis infections.
These infections are especially relevant for patients whose immune
systems have been compromised, such as patients undergoing bone
marrow transplantation (BMT) or chemotherapy. IFIs are also a
significant cause of morbidity and mortality in patients with
hematologic malignancies. The 90-day mortality rate in patients who
have a hematologic malignancy or undergo BMT and are then diagnosed
with an IFI ranges from 52 to 63 percent.
Specifically, presented data will demonstrate the following
potential advantages of rezafungin as compared to the current
antifungal standard of care: in vitro activity against
azole-resistant Aspergillus; the high concentrations of rezafungin
distributing into the lungs; and the rationale for dose selection
for the prevention of Aspergillus, Candida and Pneumocystis
infections in BMT patients.
Details of the Cidara AAA and BMT Tandem Meetings presentations
are as follows:
AAA Conference Presentations (Lisbon, Portugal)
Thursday, February 1: Optimizing Anti-Aspergillus
Therapy (9:20 a.m. – 10:55 a.m., WET, Lisboa Congress
Centre)
- Abstract #9: The investigational echinocandin CD101
demonstrates potent in vitro activity against Aspergillus
fumigatus, including azole-resistant isolates; N. Wiederhold, et.
al. (9:45 a.m. – 10:00 a.m.)
Thursday, February 1 – Saturday, February 3: Poster on
Display during Conference
- CD101 Lung Tissue and Epithelial Lining Fluid (ELF)
Concentrations Substantiate Its Use For Prophylaxis Treatment As
Evident In Mouse Disseminated and Pulmonary Aspergillosis Models;
V. Ong, et. al.
2018 BMT Tandem Meetings Presentations (Salt Lake City,
Utah)
Saturday, February 24: Poster Session II - (6:45 p.m.
-7:45 p.m., MST, Salt Palace Convention Center, Hall
E)
- Poster #554: CD101, 'a Perfect Storm’ Against Aspergillus: In
Vitro Microbiology, In Vivo Tissue Distribution, and Front Loaded
Treatment and Prophylactic Efficacy in Mouse Disseminated and
Pulmonary Aspergillosis Infection Models, V. Ong, et. al.
- Poster #568: CD101 Prophylactic Dose Rationale for Prevention
of Aspergillus, Candida, and Pneumocystis Infections, S. Flanagan,
et. al.
Copies of these posters and presentations will be available on
the Cidara website following the meetings: www.cidara.com.
About Invasive Fungal Infections
Invasive fungal infections (IFIs) represent a serious threat to
millions of patients worldwide, resulting in more than 1.5 million
deaths annually and mortality rates ranging from 15 to 65 percent.
These infections continue to be a global health issue, especially
for critically ill patients in hospitals and patients with
compromised immune systems. Of the most significant IFIs,
approximately 90 percent of related deaths are primarily caused by
Candida, Aspergillus, and Pneumocystis. Candida species are most
common in hospital-acquired infections, while Aspergillus species
are predominant in patients with weakened immune systems or lung
diseases. Pneumocystis infections also commonly afflict
immunocompromised patients.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on
developing new anti-infectives that have the potential to transform
the standard of care and save or improve patients’ lives. The
company is currently advancing its novel echinocandin antifungal,
rezafungin acetate, formerly called CD101 IV, through Phase 2 and
developing CD201, its bispecific antibiotic immunotherapy, for the
treatment of multi-drug resistant Gram-negative bacterial
infections. Rezafungin has improved pharmacokinetics compared to
existing echinocandins and has the potential for expanded utility
across patient settings. Rezafungin is the only once-weekly product
candidate in development for the treatment and prevention of
life-threatening invasive fungal infections. CD201 is the first
drug candidate selected from Cidara’s novel Cloudbreak™ platform,
the first immunotherapy discovery platform designed specifically to
create compounds that directly kill pathogens and also direct a
patient’s immune cells to attack and eliminate bacterial, fungal or
viral pathogens. Cidara has received a grant for up to $6.9 million
from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator)
to advance the development of CD201 and back-up molecules. Cidara
is headquartered in San Diego, California. For more information,
please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, the effectiveness,
safety, and other attributes of rezafungin and other potential
product candidates, including the potential for these compounds to
successfully treat or prevent infections, including those caused by
resistant pathogens, and augment treatment and prophylaxis
strategies in the future, and the potential for rezafungin to have
advantages over the current standard of care in the treatment or
prevention of invasive fungal infections. Risks that contribute to
the uncertain nature of the forward-looking statements include: the
success and timing of Cidara’s preclinical studies and clinical
trials; regulatory developments in the United States and foreign
countries; changes in Cidara’s plans to develop and commercialize
its product candidates; Cidara’s ability to obtain additional
financing; Cidara’s ability to obtain and maintain intellectual
property protection for its product candidates; and the loss of key
scientific or management personnel. These and other risks and
uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
INVESTOR CONTACT:Robert H. UhlWestwicke
Partners, LLCManaging Director(858)
356-5932robert.uhl@westwicke.com
MEDIA CONTACT:Christy Curran Sam Brown
Inc.615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Apr 2023 to Apr 2024